Heat Biologics Inc. (Nasdaq: HTBX) reported disappointing results from a Phase 2 trial of its bladder cancer treatment HS-410. Shares of the biopharmaceutical plummeted $1.84 to close at $1.03.
Heat Biologics disappoints
December 01, 2016 at 19:52 PM EST
